Letter to the Editor Serum Immunoglobulin E After Myocardial Infarction
To the Editor:
Szczeklik et all have presented interesting data recently in Circulation showing a sharp rise in serum immunoglobulin E (lgE) after myocardial infarction, which is followed by a return to normal levels by about 3 weeks. They further state that patients with high baseline IgE levels (>200 IU/ml) had a more benign course than those with lower levels, that the patients' distribution of IgE levels at baseline was comparable to normal population values, and that a previous report2 from our research group of high IgE levels in patients with myocardial infarction may reflect persistently elevated levels in a few patients.
Their assertation of a more benign course with higher IgE levels is based on severe complications in 1 of 16 (6%) patients with high IgE levels compared with 17 of 84 (20%) patients with lower IgE levels. Although suggestive, this difference is far from being statistically significant (z = 1.33, p= 0. 18, two-tailed test for difference in independent proportions). In addition, the cut-off point of 200 IU/mI is arbitrary. For instance, the severe complication rate for IgEs between 100 and 200 IU/ml, which are clearly elevated levels, was 5 of 17 (29%), a higher rate than for those with IgE levels <100 IU/ml, which was 13 of 67 (19%).
Regarding their patients' IgE levels, contrary to the authors' assertion of comparability to the general population, the baseline levels are quite high, with a mean of 76 IU/ml. The study by Barbee et al,3 which they reference, found dramatically lower 1gE levels in the comparable age group (45-64 years), with average IgE levels of 17-33 IU/ml. Similarly, our data show mean IgE levels of about 20 IU/ml for women and 30 IU/ml for men in this age group.2 Thus, the elevated IgE levels in their study support our suggestion of an association between IgE and cardiovascular disease. Their suggestion that our results could be explained by persistent elevations of IgE in a few patients is untenable given the magnitude of the associations in our study. In addition, IgE elevations in our study were also found in patients with previous stroke and with extant peripheral arterial disease. Finally, the authors' own data (their Table 1 ) actuallv shows lower IgE levels (mean, 63 IU/ml) at day 21 than at baseline (mean, 76 IU/ml).
Thus, the study by Szczeklik et al' provides little support for a protective role of IgE in the development or subsequent course of myocardial infarction. On the contrary, it appears that in both their study and ours subjects with elevated IgE levels may be at increased risk of cardiovascular disease. As the authors note. there appears to be a complex interplay of mediators released by mast cells, and at least some of these effects could be deleterious to cardiac function. What is needed are prospective data on the relation of 1gE levels to subsequent cardiovascular disease and further study of the effects of 1gE-mediated mast cell products on cardiovascular function. Such research could provide valuable and novel insights into the pathophysiology of cardiovascular disease.
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